TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percent of time INR is in therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Occurrence of Local Skin Reaction Side Effects Total Composite Score
Endpoint domain: Adverse events/effects
Primary endpoint: Spinal anesthesia failure
Endpoint domain: Adverse events/effects
Primary endpoint: Electronic measure of needle disposals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of Myopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CT-scan results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KT1000 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Timed 25 Foot Walk (T25FW) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of head and neck cancer patients recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Child Behavior Checklist Internalizing Problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Behavior Checklist Externalizing Problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent report of total child behavior problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in AIMS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in patient's cognitive dysfunction evaluated by WCST
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in patient's cognitive dysfunction evaluated by DST
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in patient's cognitive dysfunction evaluated by DSST
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in patient's cognitive dysfunction evaluated by MoCA
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitudes Toward Computers Questionnaire Total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Brief Visuospatial Memory Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Wound healing change over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence Rate of specific infectious diseases
Endpoint domain: Adverse events/effects
Primary endpoint: Total desflurane consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Summed pain intensity difference (SPID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fusion Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of eligible women that agree to participate in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to aspirin if prescribed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of study subjects with a completed screening test who are issued the screening result within one week
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diagnosis accuracy of somatic burden assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratio of isotopic enrichment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Liver attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minmaxMF-DFA value during the tapping test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of imaging position and timing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Imaging of functional properties of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in the percentage of embedded scaffold struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Client outcomes on primary drug and alcohol measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of nifurtimox in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-tlast) of nifurtimox in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of nifurtimox in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of esophageal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of traumatisms
Endpoint domain: Adverse events/effects
Primary endpoint: Gross Motor Function Measure Scale (GMFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed toxicity using CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in psoriasis area and severity index score by 75% (PASI75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of needle passages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Alteration in gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance to development of coronary atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Forced vital capacity %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to the healing of a digital ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Disease activity score 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reference values obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in suicidal ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in macular pigment optical density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum lutein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Range of motion in burned joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood level T cell in ITP patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood level T cell in healthy controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood level T cell in ITP patients after treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum Cystatin-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in serum angiopoietin-2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with successful evaluable biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Fungicidal Activity (EFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Intrapartum Fetal Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Number of Infants With Apgar Score <= 3 at 5 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ACF biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Persistent post-surgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of tomotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of INR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Reading Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Decoding Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Reading Understanding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of administered red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and tolerability of DVS SR
Endpoint domain: Adverse events/effects
Primary endpoint: Hair growth and/or hair loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severity and death
Endpoint domain: Mortality/survival
Primary endpoint: Adverse events that require study treatment interruption
Endpoint domain: Adverse events/effects
Primary endpoint: Change in supersaturation of calcium oxalate / phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of inserts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnostic accuracy of TAPSE measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: [18F]flumazenil binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: abundance of fecal Bacteroidetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sputum White Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sputum Neutrophil Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sputum Neutrophil Percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Underexposure to antimicrobial therapy
Endpoint domain: Adverse events/effects
Primary endpoint: osseointegration of the dental implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Response rate as assessed by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient assessment after catheter removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-segment Late Loss (LL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: change in urinary protein/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in the Number of Liquid-containing Reflux Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total Hip BMD Percent Change From Baseline at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to onset of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary flow using corrected Thrombolysis In Myocardial Infarction Frame Count (cTFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression free survival rate at Month 6
Endpoint domain: Mortality/survival
Primary endpoint: Positive culture rates of blood and bile juice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: generic quality of life score SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: specific quality score CarGOQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Early neurological recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Visual Dryness 5-point Severity Score for Total Body Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Composite Pelvic Signs and Symptom Scale (CPSSS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 year Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Flavor perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated dose of lenalidomide
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of DLTs after course 1
Endpoint domain: Adverse events/effects
Primary endpoint: Overall response rate (complete response + partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Nocturnal hypoventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improved Attentional Flexibility
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improved Attentional Control
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Increased Social Orienting to Parent
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: inflammatory marker in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sputum total cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum differential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum levels of IL-1 and TNF alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total time for lesion removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Hearing In Noise Test (HINT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric Pain Rating Scale (NPRS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Extent of the arthrogenic muscle inhibition (AMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximal knee adductor moment (EKAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximal hip adduction moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Anaesthesia depth consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Complete Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Sustained Virologic Response at 6 Months Post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Relapsed at 6 Months Post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Management
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with any adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of mediastinoscopies needed to detect one additional N2/3
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean CHA2DS2-VASc Risk Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fat burning in toddlers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biological correlates of outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LA size measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of serious adverse events (SAE), adverse events of special interest (AESI), medically-attended AEs, and new onset of chronic illness
Endpoint domain: Adverse events/effects
Primary endpoint: change in reactive hyperemia index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the dimensions of the bone defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fecal incontinence score: Wexner score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Manual Dexterity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Upper Extremity Functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days of retention in outpatient treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Progression-free Survival at 2 Year
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Physician assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Percent Change in Low Density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetic parameters for VWF RCo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of ECF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intragastric pressure during liquid meal infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients with HIV plasma viral load < 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of porcine/human cysticercosis cases
Endpoint domain: Adverse events/effects
Primary endpoint: genetic abnormalities identified at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: structural anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive differences
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Grade IV granulocyte toxicity or Grade III drug-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Ease of Lens Handling at Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ultrasonic neuroma size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual limb pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Number of subjects with HCV RNA viral response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Non-relapse Participant Mortalities
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Grades III-IV Acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Basal energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients moving without anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry Low Back Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fear Avoidance Beliefs Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Insertion Torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: RFA Implant Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dimensions of Periapical Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid intimal media thickness (CIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in Brain Oxygen Tension levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes of Visual learning test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes of Korean Version of the Montreal Cognitive Assessment(MoCA-K)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinical benefit (PR, CR, SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Click Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of composite adverse outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Comfort Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Patients Experiencing Dose-Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Dichotomized Glasgow Outcome Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of completed cognitive tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to tolerating a low residue diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in compensation use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Individuals Screened and Eligible for Participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use